The Oncology Institute, Inc. (TOI) Misses Q2 EPS by 4c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance
August 8, 2023 4:40 PM EDTCERRITOS, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (TOI or the Company), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and six months ended June 30, 2023 and reaffirmed its full year 2023 guidance.
Recent Operational Highlights:
Completed the acquisition of Southland Radiation Oncology Network (SRON)Signed a new partnership with Massive Bio to further enhance randomization of trialsIncreased patient visits 14% compared to... More